RPTX: Repare Therapeutics, Inc.
About
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded on September 6, 2016 and is headquartered in Saint-Laurent, Canada.
Current Value
$2.891 Year Return
Current Value
$2.891 Year Return
Key Details
Market Cap
$122.43M
P/E Ratio
-1.44
1Y Stock Return
-39.50%
1Y Revenue Growth
18.19%
Dividend Yield
0.00%
Price to Book
0.7
Strategies that include RPTX
Stock's related to RPTX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VIR | 43.48% | $954.40M | -26.51% | 0.00% |
| ADPT | 40.75% | $661.15M | +6.16% | 0.00% |
| PGEN | 40.39% | $228.91M | -28.00% | 0.00% |
| ALEC | 40.15% | $377.04M | -19.46% | 0.00% |
| TVTX | 39.73% | $1.51B | +207.79% | 0.00% |
| CLFD | 39.61% | $398.66M | +4.48% | 0.00% |
| LOVE | 38.74% | $513.90M | +78.25% | 0.00% |
| MRSN | 38.05% | $274.24M | +40.51% | 0.00% |
| INMD | 37.49% | $1.50B | -21.29% | 0.00% |
| ARCT | 37.36% | $489.20M | -21.27% | 0.00% |
| ZUMZ | 36.26% | $409.63M | +17.32% | 0.00% |
| IBEX | 36.22% | $333.12M | +12.01% | 0.00% |
| PTGX | 36.13% | $2.30B | +122.64% | 0.00% |
| CRNX | 36.06% | $5.12B | +84.27% | 0.00% |
| CGNT | 36.01% | $501.83M | +59.73% | 0.00% |
| CRCT | 36.00% | $1.12B | -19.90% | 1.91% |
| ALLO | 35.97% | $444.50M | -24.82% | 0.00% |
| XPER | 35.39% | $378.82M | -19.06% | 0.00% |
| PSTX | 35.19% | $269.98M | +6.13% | 0.00% |
| ARLO | 34.89% | $1.20B | +31.21% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ELV | -0.06% | $91.42B | -16.23% | 1.61% |
| QNTM | -0.06% | $9.19M | -94.36% | 0.00% |
| AON | -0.10% | $82.00B | +16.33% | 0.70% |
| AZN | 0.11% | $197.82B | -0.75% | 2.33% |
| XGN | -0.14% | $62.26M | +127.74% | 0.00% |
| UEC | -0.15% | $3.54B | +34.59% | 0.00% |
| UNH | 0.20% | $531.00B | +6.93% | 1.37% |
| LIN | 0.32% | $211.44B | +7.81% | 1.23% |
| NU | -0.34% | $63.92B | +64.95% | 0.00% |
| NAT | 0.39% | $636.83M | -30.05% | 13.79% |
| IMNN | -0.55% | $10.02M | -22.89% | 0.00% |
| GRAL | -0.56% | $459.22M | -13.00% | 0.00% |
| CNSL | -0.58% | $548.51M | +9.98% | 0.00% |
| ZI | -0.58% | $3.40B | -28.47% | 0.00% |
| MAX | 0.67% | $681.47M | +32.02% | 0.00% |
| AXS | 0.68% | $7.14B | +55.12% | 2.06% |
| EG | 0.76% | $15.92B | -8.98% | 2.02% |
| HDSN | -0.79% | $260.34M | -54.39% | 0.00% |
| TKO | 0.91% | $10.62B | +67.14% | 0.00% |
| RILY | -0.91% | $145.72M | -79.86% | 20.75% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| STG | -16.50% | $35.67M | +7.92% | 0.00% |
| ACGL | -13.69% | $36.00B | +16.84% | 0.00% |
| CME | -12.62% | $82.76B | +9.21% | 1.98% |
| MMC | -12.47% | $108.41B | +10.89% | 1.37% |
| TCTM | -12.01% | $8.10M | -42.99% | 0.00% |
| OCX | -10.62% | $42.93M | -36.09% | 0.00% |
| PULM | -10.41% | $19.83M | +202.98% | 0.00% |
| CAH | -10.09% | $28.64B | +12.14% | 1.70% |
| RNR | -9.43% | $13.74B | +23.09% | 0.58% |
| MCK | -9.39% | $78.15B | +35.51% | 0.42% |
| VZIO | -8.81% | $2.29B | +67.76% | 0.00% |
| AJG | -8.40% | $64.17B | +17.51% | 0.80% |
| AFL | -8.37% | $61.74B | +35.69% | 1.35% |
| WM | -8.18% | $87.92B | +27.58% | 1.34% |
| RSG | -8.12% | $66.05B | +31.79% | 1.04% |
| COR | -8.11% | $47.48B | +21.20% | 0.86% |
| PGR | -7.87% | $149.10B | +57.29% | 0.45% |
| TW | -7.75% | $28.66B | +42.39% | 0.29% |
| MNOV | -7.74% | $93.19M | +2.15% | 0.00% |
| MNR | -7.38% | $1.66B | -10.71% | 15.90% |
ETF's related to RPTX
News
Yahoo
Repare Therapeutics Inc. ( NASDAQ:RPTX ) shareholders will have a reason to smile today, with the analysts making...
Yahoo
CAMBRIDGE, Mass. & MONTREAL, November 12, 2024--Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Yahoo
CAMBRIDGE, Mass. & MONTREAL, November 07, 2024--Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
Yahoo
It is observed that the dose optimisation significantly reduced grade 3 anaemia rates from 51.4% to 22.6%.
Yahoo
CAMBRIDGE, Mass. & MONTREAL, October 23, 2024--Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Yahoo
Repare stock gains 8% as the company initiates dosing patients in its phase I study of the RP-3467 combo regimen for advanced solid tumor indications.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.